Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Recipients of allogeneic stem cell transplantation

AstraZeneca

Astra Zeneca AB

AstraZeneca patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
cambridge, GB HQ
79,242 Employees
EMA registrant Type
Company details
Status
Public
HQ
cambridge, GB
Employees
79,242
Programs
1
Drugs
8
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

AstraZeneca patents

25 pharmaceutical patents indexed for AstraZeneca. 1 expire within 24 months.

AstraZeneca has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

25 patents

Patent portfolio

  1. IL 240179

    Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject

    Expires Sun Dec 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. ZA 201308176

    THERAPEUTIC TREATMENT

    Expires Tue Dec 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. SI 2158199

    PIPERIDINE COMPOUNDS AND USES THEREOF

    Expires Sun Feb 23 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 2010280048

    Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase

    Expires Wed Oct 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. DO P2009000148

    DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES

    Expires Thu Oct 10 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. EP 2086964

    BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN

    Expires Tue Aug 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. EP 2079730

    MGLUR5-MODULATOREN

    Expires Tue Jul 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. EP 2064340

    VERFAHREN ZUR BEWERTUNG VON PATIENTEN BEI DER BEHANDLUNG MIT AUF RET-REZEPTOR-TYROSINKINASE ABZIELENDEN ARZNEISTOFFEN

    Expires Tue May 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. AU 2008328307

    5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents

    Expires Wed May 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. AR 065278

    SALES DE DERIVADO DE BENZOTIAZOL

    Expires Tue May 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. AR 065277

    COMBINACIONES DE BENZOTIAZOLONA AGONISTA 2-BETA-ADRENOCEPTOR

    Expires Tue May 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. EP 2061775

    SPIRO-OXAZOLIDINON-VERBINDUNGEN UND IHRE VERWENDUNG ALS VERSTÄRKER METABOTROPER GLUTAMATREZEPTOREN

    Expires Tue May 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. EP 2057147

    PYRIMIDIN-DERIVATE

    Expires Tue May 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. AR 065042

    DERIVADOS DE CINNOLINA, PROCESOS DE OBTENCION Y COMPOSICIONES FARMACEUTICAS

    Expires Tue May 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. AR 064864

    COMPUESTOS ANALOGOS DE PIRIDINA VII 543 Y COMPOSICION FARMACEUTICA

    Expires Tue Apr 24 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. EP 2046782

    IMIDAZOLYLPYRIMIDINDERIVATE ZUR BEHANDLUNG VON MIT GLYKOGENSYNTHASEKINASE (GSK3) IN ZUSAMMENHANG STEHENDEN KRANKHEITEN

    Expires Tue Apr 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. EP 2044050

    NEUE PYRIDINANALOGA

    Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. AR 064495

    DERIVADOS DE PIPERIDIN-CARBONILFENIL SULFONAMIDAS

    Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. EP 2044063

    FÜR DIE BEHANDLUNG VON KREBS GEEIGNETE PYRIMIDINDERIVATE

    Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. EP 2044019

    3-OXOISOINDOLIN-1-CARBONSÄUREAMIDDERIVATE ALS ANALGETIKA

    Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. EP 2041135

    ALS MODULATOREN VON TLR7 WIRKENDE 8-OXOADENINDERIVATE

    Expires Tue Mar 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. EP 2041176

    ANTIKÖRPERMOLEKÜLE FÜR HUMANES IL-17

    Expires Tue Mar 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. EP 2041112

    NEUE PYRIDINANALOGA

    Expires Tue Mar 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. EP 2035418

    NEUE HETEROARYLSUBSTITUIERTE BENZOXAZOLE

    Expires Tue Mar 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. AU 2007271920

    Benzyl amines, a process for their production and their use as anti-inflammatory agents

    Expires Wed Jan 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does AstraZeneca have?

25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do AstraZeneca patents expire?

1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.